| HS Code | 436686 |
| Product Name | Maxing Ergao Pills Veterinary Grade API |
| Api Type | Phytogenic active pharmaceutical ingredient |
| Veterinary Grade | Yes |
| Target Dosage Forms | Tablets; Injections; Capsules; Powders; Granules; Premix; Solutions |
| Pharmacological Class | Respiratory anti-inflammatory and antitussive agent |
| Active Constituents | Ephedrine-like alkaloids, amygdalin, glycyrrhizin, and mineral components |
| Primary Indications | Relief of cough, wheezing, phlegm, and respiratory inflammation in animals |
| Target Species | Poultry, swine, cattle, sheep, goats, and companion animals |
| Administration Route Compatibility | Oral and water-soluble formulations; injectable after appropriate compounding |
| Physicochemical Form | Fine dry extract or crystalline solid |
| Solubility Profile | Partially soluble in water; soluble in aqueous alcohol-based vehicles under formulation |
| Ph Stability Range | 4.0 to 8.0 |
| Storage Conditions | Store in sealed, cool, dry, light-protected conditions |
| Shelf Life | 24 months from date of manufacture |
| Quality Standard | Veterinary API specification with identity, assay, and impurity controls |
| Manufacturing Compliance | Manufactured under GMP-aligned veterinary standards |
As an accredited Maxing Ergao Pills Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Maxing Ergao Pills Veterinary Grade API is processed as a dry-milled fraction in tablet lines serving porcine and poultry respiratory-therapy intermediates, where the active component is standardized to a bulk density of 0.45–0.60 g/cm³ and a loss on drying value not exceeding 5.0% via USP Chapter 921. Compliance for this non-sterile oral solid segment falls under 21 CFR Part 210/211, with release testing anchored to USP Chapter 905 for uniformity of dosage units, USP Chapter 701 for disintegration, and USP Chapter 711 where a dissolution profile is registered. Formulation addition ratios are constrained by hygroscopicity and tablet hardness response; the API is typically incorporated at 20.0–35.0% w/w of the core granulation, with microcrystalline cellulose at 25–40% w/w, croscarmellose sodium at 2–5% w/w, colloidal silicon dioxide at 0.5–1.0% w/w, and magnesium stearate at 0.5–1.5% w/w. Downstream processing on production-scale equipment uses a 16-station rotary tablet press with compression force held at 8–14 kN and pre-compression dwell time not less than 30 ms; fluid-bed drying endpoint is 1.5–2.5% residual moisture, and friability is controlled to ≤0.8% per USP Chapter 1216. Terminal finished forms are non-sterile film-coated tablets for oral administration in pigs and poultry, typically compressed to 100 mg, 250 mg, and 500 mg core weights, with granule intermediates supplied in bulk to downstream veterinary pharmaceutical packaging sites. A processing boundary applies at relative humidity above 60%: the milled API should be pre-dried in a shallow-bed vacuum dryer at 40–45°C for 4–6 h before dry blending, otherwise particle agglomeration can raise content-uniformity rejection rates on high-speed lines.
Water-soluble powders and granules for poultry drinking-water administration present the narrowest moisture and particle-size processing window among the dry oral platforms. Regulatory compliance is governed by Regulation (EU) 2019/6 and 21 CFR Part 210/211 where the product is exported to the United States; water content must meet USP Chapter 921 Method Ia with a release limit of ≤3.0%, and reconstitution quality is assessed by a wet-sieving method over a 75 µm screen. Formulation addition ratio varies with carrier selection: a spray-dried intermediate containing 15.0–25.0% w/w API on maltodextrin DE 10–15 is dry-blended to a target active content of 10.0–20.0% w/w in the final sachet fill, with sodium chloride at 0.5–1.0% w/w added to support osmotic dispersion in hard water. Production begins with high-shear dispersion of the API and carrier at 20–30% total solids in purified water at 30–40°C; spray-drying is performed on a co-current rotary atomizer with inlet temperature 160–180°C, outlet temperature 75–85°C, and atomizer wheel speed 18,000–22,000 rpm. The resulting powder is ribbon-blended for 15–20 min, then filled into aluminum-foil laminate pouches at room humidity not exceeding 30% RH. Terminal product types include 100 g, 500 g, and 1 kg water-soluble powder sachets, plus 50 g measuring-chamber granules for poultry drinking-water proportioners. Spray-dryer outlet temperature is the critical limit: above 85°C, the active fraction can undergo surface caramelization that reduces cold-water reconstitution yield below 95%, while below 75°C residual moisture rises above the 3.0% release ceiling and initiates sachet headspace caking.
Because aseptic processing precludes terminal steam sterilization, injectable manufacturing for cattle, swine, and equine fever-respiratory protocols is constrained by pH drift, subvisible particulate load, and filter compatibility. Compliance is driven by EU GMP Annex 1, 21 CFR Part 211.42, USP Chapter 71, USP Chapter 85, and USP Chapter 788 for particulate matter; container-closure integrity is tested per USP Chapter 1207 on every batch. Formulation addition ratios are set by solubility and pH stability: the API is dissolved at 5.0–12.0% w/v in Water for Injection at 40–50°C, with sodium chloride at 0.65–0.90% w/v for isotonic adjustment and benzyl alcohol at 0.5–1.0% v/v as preservative in multi-dose vials. The solution is pH-adjusted to 5.5–6.5 using 0.1 M hydrochloric acid or sodium hydroxide. Production-scale handling includes activated carbon adsorption at 0.05–0.10% w/v with a 30 min contact time at 60°C, followed by clarification through 0.45 µm PVDF membrane and sterilizing filtration through 0.22 µm PVDF filter capsules before aseptic filling into amber glass vials under nitrogen headspace. Terminal product types are 20 mL, 50 mL, and 100 mL multi-dose vials and 10 mL single-dose vials. The critical operational boundary is thermal degradation: terminal steam sterilization at 121°C for 15 min is generally avoided because it accelerates extraction-derived color change and subvisible marker precipitation. A pH drift above 7.0 during hold times longer than 12 h at 2–8°C can generate visible aggregates, so buffering is evaluated only when the registered monograph permits it. Published data for this specific veterinary API in aseptic multi-dose vials is limited; the above in-process limits are standard for botanically similar injectable actives.
| Dosage platform | Critical in-process parameter | Control limit | Reference method |
|---|---|---|---|
| Non-sterile tablet core | friability | ≤0.8% | USP Chapter 1216 |
| Water-soluble granule | loss on drying | ≤3.0% | USP Chapter 921 Method Ia |
| Injectable solution | subvisible particulate count | passes ≥10 µm / ≥25 µm limits | USP Chapter 788 |
| Feed premix | mix homogeneity CV | ≤5.0% | ISO 6497:2002 |
| Oral capsule granulation | particle size D90 | ≤500 µm | ISO 13320:2020 |
| Oral solution | pH drift at 25°C | 5.0–6.5 | Ph. Eur. 2.2.3 |
Feed premix lines for swine and poultry integrate the active component through stepwise dilution into ground corn or rice hull carriers to minimize segregation during bulk transport. Regulatory controls under Regulation (EU) 2019/4 for medicated feed, GMP+ Feed Safety Assurance for cross-contamination limits, and ISO 6497:2002 for sampling and homogeneity apply. The intermediate premix is prepared at 10.0–20.0% w/w active component on carrier, then diluted to a final complete-feed inclusion rate of 200–1000 g/t depending on regional registration and target species; the first dilution step uses a 1:10 ratio and the second 1:100 ratio in a horizontal paddle mixer. Mixing is retained for 8–12 min at 25–35 rpm, with homogeneity verified by near-infrared spectroscopy or HPLC marker assay to a coefficient of variation not exceeding 5.0%. Downstream pelletizing requires a conditioning step held at 70–80°C for 30–60 s; pellet die compression is maintained at 2.5–3.5 MPa to minimize extrusion hardening. Terminal product types are mash premix bags, pelleted complete feed, and crumbled feed for pig and poultry production. The main incompatibility is prolonged conditioning above 85°C; this causes moisture-driven bridging in the conditioner and may reduce marker-compound assay at the die outlet by an operationally significant degree. When high-temperature pelleting is specified for feed hygiene, the API is preferably applied post-pellet via liquid coating or micro-dosing. Published data for this specific premix configuration is limited; the CV and temperature limits derive from medicated premix homogeneity standards rather than outcome-specific poultry field data.
To avoid aqueous granulation-induced agglomeration and poor powder flow at direct-compression pressures, veterinary capsule lines serving companion-animal and small-ruminant protocols use a dry-granulation route. Compliance for this non-sterile oral solid form requires 21 CFR Part 211.110 in-process control, USP Chapter 905 content uniformity, USP Chapter 701 disintegration, and USP Chapter 711 dissolution if the registered label specifies a dissolution profile. The formulation addition ratio is higher than in tablets to allow fill weight reduction: API at 30.0–45.0% w/w, dicalcium phosphate dihydrate at 25–40% w/w, crospovidone at 2–4% w/w, and magnesium stearate at 0.5–1.0% w/w. Roller compaction is conducted at 70–110 bar hydraulic pressure to produce ribbons with density 1.05–1.20 g/cm³; milled granules are screened to target a D90 below 500 µm on an oscillating granulator. Encapsulation is performed on an intermittent-motion capsule filler with pin opening force set at 40–60 N for size 0 and size 1 HPMC capsules, and fill weight is checked at 15 min intervals. Terminal product types are 250 mg and 500 mg HPMC capsules in blister and HDPE bottle formats. The operational boundary is moisture uptake: the granulated intermediate must be held below 40% RH and filled within 72 h of roller compaction; otherwise capsule shell brittleness and granule clumping can raise reject rates above normal line capability.
Non-sterile liquid oral administration lines that prepare drench and drinking-water solutions handle the API under a different set of solubility and microbial-quality constraints than dry oral solids. Applicable compliance points include Regulation (EU) 2019/6, USP Chapter 795 for non-sterile compounding, and ISO 22000:2018 for food-safety prerequisites when the solution is distributed through integrated feed and water systems. Formulation addition ratios are held at 2.0–8.0% w/v API in purified water, with propylene glycol at 5–15% v/v as cosolvent, sodium benzoate at 0.1–0.2% w/v as preservative, and disodium edetate at 0.01–0.05% w/v to chelate metal ions that would otherwise catalyze oxidative browning. Production is executed in 316L stainless steel mixing vessels using a high-shear disperser at 1,500–3,000 rpm for 20–30 min; the batch is then clarified through a 0.45 µm polypropylene filter to remove undissolved residues and filled into amber bottles equipped with graduated dosing chambers. Terminal product types are 100 mL, 250 mL, and 1 L oral solution bottles and 500 mL drench containers for sheep and goats. The main limitation is chemical stability: exposure to direct sunlight and temperatures above 30°C for more than 90 days can reduce marker-compound recovery, and mixing with alkaline hard water above pH 8.0 may induce visible precipitation within 24 h. No further stabilization beyond the registered antioxidant–chelator system should be introduced without a stability-indicating assay.
Competitive Maxing Ergao Pills Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Maxing Ergao Pills Veterinary Grade API is supplied as a multi-component botanical extract standardized for formulation into seven veterinary dosage-form routes: tablets, injections, capsules, powders, granules, premix, and solutions. The trade designation includes the term “Pills,” but the material is not a finished pill; it is an active pharmaceutical ingredient intermediate that may be spray-dried, vacuum-concentrated, or lyophilized depending on the dosage-form grade. Model suffixes are manufacturer-assigned and usually encode extraction ratio, marker assay range, and intended route. A typical injectable-grade suffix may indicate low-endotoxin processing, while an oral-premix suffix may indicate a silica or maltodextrin carrier matrix. The extraction ratio is commonly expressed as 5:1 or 10:1 concentrated extract, although exact model coding must be confirmed against the manufacturer’s certificate of analysis. Because this API is a multi-component herbal preparation rather than a single chemical entity, its release profile includes marker fingerprinting, residual solvent, pesticide, and elemental impurity panels. Its use in veterinary medicine is regulatory-status dependent: in some markets the final product must be registered as a veterinary medicinal product and must comply with current veterinary good manufacturing practice, while in others the same formulation may be classified as an unapproved feed ingredient.
For release control, laboratories apply orthogonal methods that usually include loss on drying by USP <731>, particle-size distribution by laser diffraction ISO 13320 or analytical sieving USP <786>, bulk density, and microbial enumeration by Ph. Eur. 2.6.12 / 2.6.13. Because a single pharmacopoeial monograph for this specific multi-herb API is not universally available, specification limits are frequently derived from process capability data across three or more production campaigns. The analytical target set typically includes at least one alkaloid marker, one flavonoid or saponin marker, and one triterpene or organic acid marker, each quantified by high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry when co-eluting matrix peaks exceed acceptance thresholds. Residual ethanol, methanol, or acetone are controlled under VICH GL18 where solvent extraction is used; elemental impurities are screened according to USP <232> / <233> or the principles of ICH Q3D for veterinary products. A release certificate that lacks particle-size, microbial, and marker-assay data is generally insufficient for dosage-form conversion.
A single-entity synthetic respiratory API such as ambroxol hydrochloride or bromhexine hydrochloride is defined by one assay, a narrow melting range, and well-characterized solubility. Its specification is transferable across compendial methods. The Maxing Ergao Pills Veterinary Grade API is instead defined by a multi-marker profile and a similarity threshold for chromatographic fingerprints. This creates a fundamentally different validation path. A formulation already validated for a synthetic bronchodilator cannot be changed to this botanical API without revalidation of blend uniformity, assay, impurities, dissolution, and stability.
| Attribute | Maxing Ergao Pills Veterinary Grade API | Single-entity synthetic respiratory API | Unstandardized botanical powder |
|---|---|---|---|
| Assay basis | Multi-marker LC-UV/LC-MS; chromatographic fingerprint similarity | Single HPLC/UV assay, typically 98.0–102.0% | Microscopic or thin-layer identity only |
| Particle-size control | Laser diffraction ISO 13320 / sieving USP <786>; form-specific D90 limit | Defined crystal habit and micronisation where needed | Simple sieve fraction, if controlled |
| Microbial and endotoxin | TAMC/TYMC per Ph. Eur. 2.6.12 / 2.6.13; BET per USP <85> for injectable grade | Low bioburden, often sterile-filtered | Variable; may exceed oral limits |
| Dosage-form range | Seven routes; injection requires form-selective purification | Limited by solubility and stability | Limited to crude powder or tea |
| Regulatory status | Veterinary API subject to GMP and VICH; marker limits dossier-specific | Compendial monograph in Ph. Eur./USP | Feed material or traditional use only |
The regulatory distinction is equally important. The source material may contain ephedrine-type alkaloids, depending on the botanical composition; these substances are subject to national controlled-substance, sport-horse, or racing restrictions in certain jurisdictions. Inventory control, documented use, and residue-marker analysis may therefore be mandatory. Unstandardized botanical powders, by contrast, usually lack controlled particle size, microbial limits, and marker release ranges; they are not reliably tableted or filled into capsules and are generally unsuitable for injectable preparation without extensive extraction and purification.
Method validation follows the same logic as for a botanical combination product. Specificity is demonstrated against the marker mix, not against a single reference standard; linearity is established over 50–150% of the marker release target; accuracy is determined at 80%, 100%, and 120% of target; precision is assessed for both intraday and interday repeats. The acceptance for a chromatographic fingerprint similarity threshold is best derived from a minimum of 3 production batches and forced-degradation samples. Degradation products in botanical extracts often overlap native minor peaks; therefore, mass balance may not be attainable by area-normalisation alone, and the stability-indicating character of the method must be confirmed by forced-degradation studies under heat, humidity, acid, base, and peroxide conditions described in VICH GL3.
Tableting, capsule filling, and granulation require a compressible powder fraction. Direct compression is rarely adequate unless the spray-dried intermediate contains a sufficient proportion of microcrystalline cellulose and copovidone; otherwise wet granulation is used. In high-shear granulation, endpoint torque is titrated against the power curve of the specific granulator bowl rather than fixed; for a large botanical tablet in the 700–900 mg range, a common target breaking force is 80–120 N, but tooling shape, punch face, and break line alter the final value. Loss on drying after wet granulation is generally controlled below 5.0% w/w to prevent picking, sticking, or tablet embrittlement. Tablet friability is tested by USP <1216>, breaking force by USP <1217>, and dissolution by USP <711>. Because the API contains both water-soluble and water-insoluble fractions, single-medium dissolution testing may fail to detect batch variability; a validated two-stage medium such as 0.1 N hydrochloric acid followed by phosphate buffer pH 6.8 with surfactant is often required.
Injectable preparation imposes the most restrictive threshold set. Endotoxin limits must be calculated from the intended species, dose, and route according to USP <85>; a common screening limit for injectable-grade botanical intermediates is NMT 0.5 EU/mg, but the final limit is dosage-species dependent. After reconstitution or dilution, the product must pass USP <788> for subvisible particulate matter and USP <71> for sterility. Terminal steam sterilisation at 121°C for 15 minutes may degrade heat-labile marker alkaloids, so filtration through a 0.22 µm membrane is frequently assessed first. Polysaccharide and pectin fractions can reduce membrane throughput; a pre-filtration trial using a 0.45 µm polyethersulfone membrane is mandatory because published data for this specific configuration is limited. The final injectable solution should be adjusted to approximately isotonicity, generally 280–320 mOsm/kg, with sodium chloride or dextrose, and pH should be selected from stability and solubility screening rather than assumed from the oral solution.
For oral powders and premixes, particle-size distribution is the main processing variable. If the D90 exceeds 150 µm and the carrier particle size is above 1000 µm, segregation becomes probable. A target inclusion below 0.1% w/w in a premix requires a 1:10 geometric pre-blend followed by a final blend in a ribbon blender for 10–15 minutes after pre-blending. Blend uniformity is confirmed by assay of all active markers rather than a single marker. A typical acceptance criterion is 90.0–110.0% of label claim with relative standard deviation not more than 5.0%. Capsule filling requires control of tapped density and angle of repose; if angle of repose exceeds 45°, filling weight variation may fail USP <905>. A glidant such as colloidal silicon dioxide at 0.5–1.0% w/w is commonly used.
For granules produced by fluid-bed granulation, inlet air temperature is usually set between 50–65°C and spray rate is adjusted to keep product temperature below 40°C to limit loss of heat-sensitive marker alkaloids. Final moisture endpoint of 2–4% w/w is common for capsule and sachet filling. For oral solution, pH is typically controlled between 4.5 and 6.5 to reduce hydrolysis of ester-type marker components; if pH drops below 4.0, precipitation of acidic polyphenolic fractions may occur. Preservative systems containing benzoic acid or sodium benzoate should be screened for interaction with polyphenol fractions; benzalkonium chloride is not acceptable for parenteral use.
Blending segregation is not a single-variable failure. It arises from the interaction of API particle size, carrier density, blend humidity, and mixer shear. In low-shear ribbon blenders, segregation failures are most often observed when the API is added directly as a fine cohesive powder without pre-blending, or when the final blend time is extended beyond the point where electrostatic charge causes fines to migrate. Pre-blend assays using a thief sampler may understate variability; full-batch discharge sampling in 10–20 locations provides a more reliable uniformity estimate. If the relative standard deviation of the pre-blend exceeds 5.0%, subsequent final blend success is unlikely.
For solutions, the critical limit is the solubility of the extract matrix. Cold-water reconstitution of a spray-dried oral-grade powder may yield a suspension rather than a true solution because heat-labile pectin and saponin fractions hydrate slowly. Warm-water hydration at 35–40°C for 20–30 minutes improves dispersion, but it does not convert the product into a sterile or particle-free injectable. Only injectable-grade material that has undergone further purification and endotoxin control should be considered for liquid parenterals.
| Dosage form | Critical attribute | Method reference | Action limit or criterion |
|---|---|---|---|
| Tablet | Friability, breaking force, dissolution | USP <1216>, USP <1217>, USP <711> | ≤ 1.0% mass loss; dissolution Q ≥ 80% at 60 min |
| Injection | Endotoxin, sterility, particulate matter | USP <85>, USP <71>, USP <788> | Endotoxin dose-species derived; sterility and particulate pass |
| Capsule | Disintegration, weight variation, moisture | USP <701>, USP <905>, USP <731> | Disintegration ≤ 30 min; weight variation per USP <905> |
| Powder | Particle-size distribution, loss on drying | ISO 13320 / USP <786>, USP <731> | D90 form-specific; LOD ≤ 5.0% w/w |
| Granule | Flow, sieving, moisture | USP <1174>, USP <786>, USP <731> | Angle of repose ≤ 45°; friability correlated to yield |
| Premix | Blend uniformity, assay, moisture | 21 CFR Part 225, USP <905> | 90.0–110.0% label claim; RSD ≤ 5.0% |
| Solution | pH, clarity, microbial limits | USP <791>, Ph. Eur. 2.2.1, USP <51> | pH per dossier; clarity and microbial limits per dossier |
Storage and packaging are form-dependent. Non-sterile oral grades are usually packed in double polyethylene bags with desiccant and stored at ≤ 25°C and relative humidity ≤ 60%. Lyophilized injectable intermediates may require 2–8°C storage if steady-state marker loss exceeds 5.0% at 25°C over 6 months. The powder should not be exposed to strong oxidizing acids, which can degrade alkaloid and flavonoid fractions; certain divalent metal ions can form tannin-metal complexes and reduce assay recovery. Because formulation-specific compatibility data are not universally available, a forced-degradation screen and a pre-formulation solubility matrix are required before invoking use in a new dosage form. The product is not interchangeable with a synthetic single-entity API or with an unstandardized botanical powder without revalidation of identity, purity, content uniformity, and stability.
